Variables | Univariate | ||
---|---|---|---|
HR | 95% CI | P | |
Risk factors for biochemical recurrence | |||
Age, years | 1.011 | 0.957–1.068 | 0.688 |
PSA at diagnosis, ng/mL | 1.088 | 0.985–1.201 | 0.094 |
Clinical stage, T2a–c versus 1c | 0.704 | 0.325–1.526 | 0.375 |
Gleason grade groups at biopsy | 0.823 | 0.472–1.436 | 0.494 |
Positive biopsy core rate, ≥ 34% versus < 34% | 0.774 | 0.344–1.740 | 0.536 |
Unfavorable versus favorable | 1.413 | 0.641–3.117 | 0.391 |
BED < 200 Gy2 versus ≥ 200 Gy2 | 0.636 | 0.294–1.378 | 0.252 |
EBRT yes versus no | 1.170 | 0.491–2.791 | 0.722 |
Risk factors for salvage hormonal therapy | |||
Age, years | 1.032 | 0.959–1.110 | 0.394 |
PSA at diagnosis, ng/mL | 0.928 | 0.799–1.079 | 0.334 |
Clinical stage, T2a–c versus 1c | 1.437 | 0.521–3.962 | 0.482 |
Gleason grade groups at biopsy | 0.931 | 0.457–1.896 | 0.846 |
Positive biopsy core rate, ≥ 34% versus < 34% | 1.147 | 0.427–3.081 | 0.785 |
Unfavorable versus favorable | 1.392 | 0.505–3.833 | 0.522 |
BED < 200 Gy2 versus ≥ 200 Gy2 | 0.964 | 0.358–2.590 | 0.942 |
EBRT yes versus no | 1.427 | 0.495–4.108 | 0.510 |